Hepatic mitochondrial beta-oxidation pathway (mtFAO) (mtFAO)

The hepatic mitochondrial beta-oxidation pathway (mtFAO) is a fundamental metabolic process responsible for the sequential breakdown of fatty acids into acetyl-CoA, which serves as a substrate for the tricarboxylic acid (TCA) cycle and ketogenesis (NIH, PMID: 7494860). This pathway is localized within the mitochondrial matrix and is critically regulated by the carnitine shuttle, primarily through the rate-limiting enzyme carnitine palmitoyltransferase 1 (CPT1) (NIH, PMID: 19691442). In the liver, beta-oxidation is essential for maintaining systemic energy balance during fasting and preventing the lipotoxic accumulation of fatty acids (ResearchGate, Massart et al., 2015). Dysregulation of this pathway is central to the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), where insufficient oxidation contributes to hepatic steatosis (MDPI, PMID: 34117519). Furthermore, many drugs, such as valproic acid and amiodarone, can inhibit this pathway, leading to drug-induced liver injury (DILI) characterized by microvesicular steatosis and severe hypoglycemia (NIH, PMID: 7494860). Therapeutic interventions often target this pathway using PPAR agonists to induce enzyme expression or ACC inhibitors to disinhibit CPT1, thereby promoting fatty acid clearance and improving metabolic health (NIH, PMID: 19691442).

Other names

Mitochondrial fatty acid beta-oxidationHepatic fatty acid oxidationFatty acid beta-oxidation pathwayMitochondrial beta-oxidation

Modulation of fatty acid entry into the mitochondria via the carnitine palmitoyltransferase (CPT) system or direct inhibition/induction of enzymes within the beta-oxidation spiral to regulate lipid catabolism and energy homeostasis.